Expertise in

conditions

Argiris S. Symeonidis

Patra, ESYE23, GR

Clinical Trials:Currently Recruiting for 1 Trial

Expertise in

conditions

Patra, ESYE23, GR

Overview

Argiris Symeonidis practices in Patra, Greece. Symeonidis is highly rated in 22 conditions, according to our data. Their top areas of expertise are Myelodysplastic Syndrome (MDS), Multiple Myeloma, Chronic Myelomonocytic Leukemia (CMML), Bone Marrow Transplant, and Splenectomy.

Their clinical research consists of co-authoring 131 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Locations

Patra, ESYE23, Greece

Other Locations

Rio, ESYE23, Greece

Irakleion, ESYE43, Greece

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Enrollment Status: Recruiting

Publish Date: October 01, 2025

Intervention Type: Drug

Study Drug: Selinexor

Study Phase: Phase 2

A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide Plus Lowdose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)

Enrollment Status: Active_not_recruiting

Publish Date: March 31, 2026

Intervention Type: Drug

Study Drugs: Belantamab Mafodotin, Pom/Dex (Pomalidomide plus Low Dose Dexamethasone)

Study Phase: Phase 3

A Phase 1/2 Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Modakafusp Alfa (TAK-573) as a Single Agent in Patients With Relapsed Refractory Multiple Myeloma

Enrollment Status: Terminated

Publish Date: January 29, 2026

Intervention Type: Drug

Study Drugs: TAK-573, Dexamethasone

Study Phase: Phase 1/Phase 2

A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Enrollment Status: Active_not_recruiting

Publish Date: November 26, 2025

Intervention Type: Drug

Study Drugs: Ponatinib, Imatinib, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone

Study Phase: Phase 3

A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Pomalidomide and Dexamethasone (B-Pd) Versus Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Participants With Relapsed/Refractory Multiple Myeloma (DREAMM 8)

Enrollment Status: Active_not_recruiting

Publish Date: March 18, 2025

Intervention Type: Drug

Study Drugs: Belantamab Mafodotin, Pomalidomide, Dexamethasone, Bortezomib

Study Phase: Phase 3

View 4 Less Clinical Trials

131 Total Publications

Clinical outcomes of patients with lower risk myelodysplastic syndrome from EUMDS registry eligible for transplantation: Implications for transplantation strategies.

Journal: British journal of haematology

Published: September 03, 2025

View All 131 Publications

Frequently Asked Questions about Argiris S. Symeonidis

Is Argiris S. Symeonidis a top-rated expert for Myelodysplastic Syndrome (MDS)?

MediFind is an objective health platform that identifies experts based on real-world data. Argiris S. Symeonidis is classified as an Elite expert for Myelodysplastic Syndrome (MDS), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Argiris S. Symeonidis participate in research or clinical trials?

Yes. Argiris S. Symeonidis has published 131 articles and abstracts on conditions like Myelodysplastic Syndrome (MDS). You can view a list of Argiris S. Symeonidis's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Symeonidis's expertise for a condition

ConditionClose